|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:academic_programs
|
gptkb:Michael_J._Rosenblatt
|
|
gptkbp:acquisition
|
gptkb:Acceleron_Pharma
gptkb:Schering-Plough
|
|
gptkbp:acquisition_year
|
gptkb:2009
|
|
gptkbp:advertising
|
gptkb:Caroline_L._Dwyer
gptkb:Diana_B._Mc_Kenzie
gptkb:Susan_L._Hockfield
gptkb:Michael_A._Rosenblatt
gptkb:Dr._Julie_Gerberding
gptkb:Mr._David_W._Johnson
gptkb:James_A._Mc_Carthy
|
|
gptkbp:ceo
|
gptkb:Robert_M._Davis
|
|
gptkbp:clinical_trial
|
gptkb:Ebola_vaccine
gptkb:vaccine
Hepatitis C treatment
collaborations with universities
conducts clinical trials
Alzheimer's treatment
Phase III trials for new drugs
collaborations with biotech companies
collaborations with research institutes
Phase I trials for new drugs
Phase II trials for new drugs
|
|
gptkbp:competitors
|
gptkb:Johnson_&_Johnson
gptkb:Astra_Zeneca
gptkb:Pfizer
gptkb:Bayer
gptkb:Novartis
|
|
gptkbp:conducts_research_on
|
gptkb:Roger_Perlmutter
gptkb:Dr._Roger_Perlmutter
|
|
gptkbp:dividend_yield
|
approximately 3.2% (2021)
|
|
gptkbp:employees
|
around 74,000 (2020)
|
|
gptkbp:founded
|
1891
|
|
gptkbp:founder
|
gptkb:George_W._Merck
|
|
gptkbp:funding
|
$12 billion (2020)
|
|
gptkbp:global_presence
|
over 140 countries
|
|
gptkbp:has_authority_over
|
gptkb:Richard_J._De_Luca
|
|
gptkbp:head
|
gptkb:David_J._Hager
|
|
gptkbp:head_of_global_corporate_affairs
|
gptkb:Michael_J._Mc_Guire
|
|
gptkbp:head_of_global_hr
|
gptkb:Kathy_A._Warden
|
|
gptkbp:head_of_global_it
|
gptkb:David_J._Hager
|
|
gptkbp:head_of_global_manufacturing
|
gptkb:David_W._Johnson
|
|
gptkbp:head_of_global_regulatory_affairs
|
gptkb:Michele_A._Heller
|
|
gptkbp:head_of_state
|
gptkb:David_W._Johnson
gptkb:Mr._John_Smith
gptkb:Kathy_A._Warden
|
|
gptkbp:headquarters
|
gptkb:Kenilworth,_New_Jersey
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Merck & Co.
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:invention
|
numerous pharmaceutical patents
|
|
gptkbp:investment
|
gptkb:Caroline_L._Dwyer
|
|
gptkbp:market_cap
|
$200 billion (2021)
approximately $200 billion (2021)
|
|
gptkbp:number_of_employees
|
approximately 74,000
|
|
gptkbp:partnership
|
gptkb:GSK
gptkb:Astra_Zeneca
gptkb:Bristol-Myers_Squibb
gptkb:IAVI
|
|
gptkbp:philanthropy
|
gptkb:Merck_Foundation
|
|
gptkbp:products
|
antibiotics
medications
vaccines
oncology drugs
diabetes medications
|
|
gptkbp:regulatory_compliance
|
gptkb:Michele_A._Heller
gptkb:Dr._Christine_Carr
|
|
gptkbp:research
|
gptkb:cancer_treatment
vaccine development
HIV treatment
|
|
gptkbp:research_focus
|
oncology
infectious diseases
vaccinology
|
|
gptkbp:revenue
|
$48.7 billion (2020)
|
|
gptkbp:stock_exchange
|
gptkb:New_York_Stock_Exchange
|
|
gptkbp:stock_symbol
|
MRK
|
|
gptkbp:strategy
|
gptkb:Michael_J._Mc_Guire
|
|
gptkbp:subsidiaries
|
gptkb:Merck_Sharp_&_Dohme
|
|
gptkbp:subsidiary
|
gptkb:Merck_Sharp_&_Dohme
|
|
gptkbp:supply_chain
|
gptkb:Ms._Sarah_Johnson
gptkb:John_A._Mc_Carthy
|
|
gptkbp:sustainability_initiatives
|
community engagement
diversity and inclusion
environmental responsibility
access to medicine
|
|
gptkbp:traded_on
|
gptkb:NYSE
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.merck.com
|
|
gptkbp:bfsParent
|
gptkb:biotechnology
gptkb:W3_C
|
|
gptkbp:bfsLayer
|
3
|